Astrazeneca Pharma India announced that the Annual General Meeting (AGM) of the company will be held on 10 September 2018.

Powered by Capital Market - Live News

The announcement was made after market hours yesterday, 16 August 2018.

Meanwhile, the S&P BSE Sensex was up 282.50 points, or 0.75% to 37,946.06.

On the BSE, 2,242 shares were traded in the counter so far compared with average daily volumes of 7,611 shares in the past two weeks. The stock had hit a high of Rs 1,777.35 and a low of Rs 1,745.80 so far during the day. The stock hit a 52-week high of Rs 1,823.40 on 3 August 2018. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

AstraZeneca Pharma India announced that it has received Import & Market permission for Olaparib (Lynparza) 100 mg and 150 mg tablets for treatment of ovarian and breast cancer in India by the Drug Controller General of India (DCGI) . The receipt of this permission paves way for the launch of Olaparib (Lynparza) in India.

AstraZeneca Pharma India reported net profit of Rs 3.22 crore in Q4 March 2018 as against net loss of Rs 9.56 crore in Q4 March 2017. Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.

AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.

Powered by Capital Market - Live News

Astrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Tablets 100 mg and 150 mg (Lynparza®). The receipt of this Import and Market permission paves way for the launch of Olaparib Tablets 100 mg and 150 mg (Lynparza®) in India, subject to the receipt of other related statutory approvals and licenses.

Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India rose 10.17% to Rs 6.39 crore in the quarter ended June 2018 as against Rs 5.80 crore during the previous quarter ended June 2017. Sales rose 26.64% to Rs 161.44 crore in the quarter ended June 2018 as against Rs 127.48 crore during the previous quarter ended June 2017.

Powered by Capital Market - Live News